Status:
COMPLETED
Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer Disease
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The objective of this study is to investigate how quickly and to what extent the 14-Carbon labeled SAM-531 is absorbed into the bloodstream, converted and eliminated from the body after oral administr...
Eligibility Criteria
Inclusion
- Men aged 18 to 50 years inclusive at screening
- Healthy as determined by the investigator on the basis of screening evaluations
Exclusion
- Presence or history of any disorder that may prevent the successful completion of the study.
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00906191
Start Date
May 1 2009
End Date
August 1 2009
Last Update
August 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuidlaren, Netherlands, 9470